Compare KREF & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KREF | ENTA |
|---|---|---|
| Founded | 2014 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 458.9M | 486.3M |
| IPO Year | 2017 | 2013 |
| Metric | KREF | ENTA |
|---|---|---|
| Price | $7.22 | $14.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $10.33 | ★ $20.40 |
| AVG Volume (30 Days) | ★ 988.7K | 219.3K |
| Earning Date | 02-03-2026 | 02-09-2026 |
| Dividend Yield | ★ 14.01% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $15,844,000.00 | ★ $66,980,000.00 |
| Revenue This Year | $571.48 | $0.99 |
| Revenue Next Year | $9.54 | $0.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 0.58 |
| 52 Week Low | $7.11 | $4.09 |
| 52 Week High | $11.53 | $17.15 |
| Indicator | KREF | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 31.09 | 58.57 |
| Support Level | $7.22 | $13.18 |
| Resistance Level | $8.40 | $15.55 |
| Average True Range (ATR) | 0.25 | 0.66 |
| MACD | -0.11 | 0.18 |
| Stochastic Oscillator | 11.01 | 59.44 |
KKR Real Estate Finance Trust Inc is a real estate finance company that focuses on originating and acquiring senior mortgage loans secured by CRE assets. The investment is to originate or acquire senior mortgage loans collateralized by institutional-quality CRE assets that are owned and operated by experienced and well-capitalized sponsors and located in liquid markets with underlying fundamentals. KKR manages investments across multiple asset classes, including private equity, real estates, energy, infrastructure, credit, and hedge funds. The company's investment objective is capital preservation and generating attractive risk-adjusted returns for its stockholders over the long term, through dividends.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.